基石藥業-B(02616.HK):授出247.3萬份購股權及376.8萬股受限制股份
格隆匯 11 月 30日丨基石藥業-B(02616.HK)宣佈,於2020年11月30日,公司根據首次公開發售後僱員持股計劃的條款向41名購股權承授人授出247.3萬份購股權,惟須待接納。,初步行使價為每股9.53港元。
此外,根據首次公開發售後受限制股份獎勵計劃,截至公告日期,於2020年6月23日至2020年11月30日期間已向33名已或將對集團增長及發展作出貢獻的受限制股份單位承授人(包括一名董事(涉及100萬股受限制股份)及集團32名其他僱員(涉及276.8萬股受限制股份))授出代表376.8萬股股份的受限制股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.